Cargando…
Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011
BACKGROUND: Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139127/ https://www.ncbi.nlm.nih.gov/pubmed/27919243 http://dx.doi.org/10.1186/s12885-016-2963-0 |
_version_ | 1782472189527719936 |
---|---|
author | Schoffer, Olaf Schülein, Stefanie Arand, Gerlinde Arnholdt, Hans Baaske, Dieter Bargou, Ralf C. Becker, Nikolaus Beckmann, Matthias W. Bodack, Yves Böhme, Beatrix Bozkurt, Tayfun Breitsprecher, Regine Buchali, Andre Burger, Elke Burger, Ulrike Dommisch, Klaus Elsner, Gudrun Fernschild, Karin Flintzer, Ulrike Funke, Uwe Gerken, Michael Göbel, Hubert Grobe, Norbert Gumpp, Vera Heinzerling, Lucie Kempfer, Lana Raffaela Kiani, Alexander Klinkhammer-Schalke, Monika Klöcking, Sabine Kreibich, Ute Knabner, Katrin Kuhn, Peter Lutze, Stine Mäder, Uwe Maisel, Tanja Maschke, Jan Middeke, Martin Neubauer, Andreas Niedostatek, Antje Opazo-Saez, Anabelle Peters, Christoph Schell, Beatrice Schenkirsch, Gerhard Schmalenberg, Harald Schmidt, Peter Schneider, Constanze Schubotz, Birgit Seide, Anika Strecker, Paul Taubenheim, Sabine Wackes, Matthias Weiß, Steffen Welke, Claudia Werner, Carmen Wittekind, Christian Wulff, Jörg Zettl, Heike Klug, Stefanie J. |
author_facet | Schoffer, Olaf Schülein, Stefanie Arand, Gerlinde Arnholdt, Hans Baaske, Dieter Bargou, Ralf C. Becker, Nikolaus Beckmann, Matthias W. Bodack, Yves Böhme, Beatrix Bozkurt, Tayfun Breitsprecher, Regine Buchali, Andre Burger, Elke Burger, Ulrike Dommisch, Klaus Elsner, Gudrun Fernschild, Karin Flintzer, Ulrike Funke, Uwe Gerken, Michael Göbel, Hubert Grobe, Norbert Gumpp, Vera Heinzerling, Lucie Kempfer, Lana Raffaela Kiani, Alexander Klinkhammer-Schalke, Monika Klöcking, Sabine Kreibich, Ute Knabner, Katrin Kuhn, Peter Lutze, Stine Mäder, Uwe Maisel, Tanja Maschke, Jan Middeke, Martin Neubauer, Andreas Niedostatek, Antje Opazo-Saez, Anabelle Peters, Christoph Schell, Beatrice Schenkirsch, Gerhard Schmalenberg, Harald Schmidt, Peter Schneider, Constanze Schubotz, Birgit Seide, Anika Strecker, Paul Taubenheim, Sabine Wackes, Matthias Weiß, Steffen Welke, Claudia Werner, Carmen Wittekind, Christian Wulff, Jörg Zettl, Heike Klug, Stefanie J. |
author_sort | Schoffer, Olaf |
collection | PubMed |
description | BACKGROUND: Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients. METHODS: Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival. RESULTS: The number of annually documented cases increased by 53.2% between 2002 (N = 4 779) and 2011 (N = 7 320). There was a statistically significant continuous positive trend in the proportion of stage UICC I cases diagnosed between 2002 and 2011, compared to a negative trend for stage UICC II. No trends were found for stages UICC III and IV respectively. Age (OR 0.97, 95% CI 0.97–0.97), sex (OR 1.18, 95% CI 1.11–1.25), date of diagnosis (OR 1.05, 95% CI 1.04–1.06), ‘diagnosis during screening’ (OR 3.24, 95% CI 2.50–4.19) and place of residence (OR 1.23, 95% CI 1.16–1.30) had a statistically significant influence on the tumour stage at diagnosis. The overall 5-year relative survival for invasive cases was 83.4% (95% CI 82.8–83.9%). CONCLUSIONS: No distinct changes in the distribution of malignant melanoma tumour stages among those aged 35 and older were seen that could be directly attributed to the introduction of skin cancer screening in 2008. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2963-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5139127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-51391272016-12-15 Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011 Schoffer, Olaf Schülein, Stefanie Arand, Gerlinde Arnholdt, Hans Baaske, Dieter Bargou, Ralf C. Becker, Nikolaus Beckmann, Matthias W. Bodack, Yves Böhme, Beatrix Bozkurt, Tayfun Breitsprecher, Regine Buchali, Andre Burger, Elke Burger, Ulrike Dommisch, Klaus Elsner, Gudrun Fernschild, Karin Flintzer, Ulrike Funke, Uwe Gerken, Michael Göbel, Hubert Grobe, Norbert Gumpp, Vera Heinzerling, Lucie Kempfer, Lana Raffaela Kiani, Alexander Klinkhammer-Schalke, Monika Klöcking, Sabine Kreibich, Ute Knabner, Katrin Kuhn, Peter Lutze, Stine Mäder, Uwe Maisel, Tanja Maschke, Jan Middeke, Martin Neubauer, Andreas Niedostatek, Antje Opazo-Saez, Anabelle Peters, Christoph Schell, Beatrice Schenkirsch, Gerhard Schmalenberg, Harald Schmidt, Peter Schneider, Constanze Schubotz, Birgit Seide, Anika Strecker, Paul Taubenheim, Sabine Wackes, Matthias Weiß, Steffen Welke, Claudia Werner, Carmen Wittekind, Christian Wulff, Jörg Zettl, Heike Klug, Stefanie J. BMC Cancer Research Article BACKGROUND: Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients. METHODS: Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival. RESULTS: The number of annually documented cases increased by 53.2% between 2002 (N = 4 779) and 2011 (N = 7 320). There was a statistically significant continuous positive trend in the proportion of stage UICC I cases diagnosed between 2002 and 2011, compared to a negative trend for stage UICC II. No trends were found for stages UICC III and IV respectively. Age (OR 0.97, 95% CI 0.97–0.97), sex (OR 1.18, 95% CI 1.11–1.25), date of diagnosis (OR 1.05, 95% CI 1.04–1.06), ‘diagnosis during screening’ (OR 3.24, 95% CI 2.50–4.19) and place of residence (OR 1.23, 95% CI 1.16–1.30) had a statistically significant influence on the tumour stage at diagnosis. The overall 5-year relative survival for invasive cases was 83.4% (95% CI 82.8–83.9%). CONCLUSIONS: No distinct changes in the distribution of malignant melanoma tumour stages among those aged 35 and older were seen that could be directly attributed to the introduction of skin cancer screening in 2008. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2963-0) contains supplementary material, which is available to authorized users. BioMed Central 2016-12-05 /pmc/articles/PMC5139127/ /pubmed/27919243 http://dx.doi.org/10.1186/s12885-016-2963-0 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Schoffer, Olaf Schülein, Stefanie Arand, Gerlinde Arnholdt, Hans Baaske, Dieter Bargou, Ralf C. Becker, Nikolaus Beckmann, Matthias W. Bodack, Yves Böhme, Beatrix Bozkurt, Tayfun Breitsprecher, Regine Buchali, Andre Burger, Elke Burger, Ulrike Dommisch, Klaus Elsner, Gudrun Fernschild, Karin Flintzer, Ulrike Funke, Uwe Gerken, Michael Göbel, Hubert Grobe, Norbert Gumpp, Vera Heinzerling, Lucie Kempfer, Lana Raffaela Kiani, Alexander Klinkhammer-Schalke, Monika Klöcking, Sabine Kreibich, Ute Knabner, Katrin Kuhn, Peter Lutze, Stine Mäder, Uwe Maisel, Tanja Maschke, Jan Middeke, Martin Neubauer, Andreas Niedostatek, Antje Opazo-Saez, Anabelle Peters, Christoph Schell, Beatrice Schenkirsch, Gerhard Schmalenberg, Harald Schmidt, Peter Schneider, Constanze Schubotz, Birgit Seide, Anika Strecker, Paul Taubenheim, Sabine Wackes, Matthias Weiß, Steffen Welke, Claudia Werner, Carmen Wittekind, Christian Wulff, Jörg Zettl, Heike Klug, Stefanie J. Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011 |
title | Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011 |
title_full | Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011 |
title_fullStr | Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011 |
title_full_unstemmed | Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011 |
title_short | Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011 |
title_sort | tumour stage distribution and survival of malignant melanoma in germany 2002–2011 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139127/ https://www.ncbi.nlm.nih.gov/pubmed/27919243 http://dx.doi.org/10.1186/s12885-016-2963-0 |
work_keys_str_mv | AT schofferolaf tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT schuleinstefanie tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT arandgerlinde tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT arnholdthans tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT baaskedieter tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT bargouralfc tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT beckernikolaus tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT beckmannmatthiasw tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT bodackyves tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT bohmebeatrix tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT bozkurttayfun tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT breitsprecherregine tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT buchaliandre tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT burgerelke tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT burgerulrike tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT dommischklaus tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT elsnergudrun tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT fernschildkarin tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT flintzerulrike tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT funkeuwe tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT gerkenmichael tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT gobelhubert tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT grobenorbert tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT gumppvera tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT heinzerlinglucie tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT kempferlanaraffaela tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT kianialexander tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT klinkhammerschalkemonika tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT klockingsabine tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT kreibichute tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT knabnerkatrin tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT kuhnpeter tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT lutzestine tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT maderuwe tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT maiseltanja tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT maschkejan tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT middekemartin tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT neubauerandreas tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT niedostatekantje tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT opazosaezanabelle tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT peterschristoph tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT schellbeatrice tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT schenkirschgerhard tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT schmalenbergharald tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT schmidtpeter tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT schneiderconstanze tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT schubotzbirgit tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT seideanika tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT streckerpaul tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT taubenheimsabine tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT wackesmatthias tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT weißsteffen tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT welkeclaudia tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT wernercarmen tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT wittekindchristian tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT wulffjorg tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT zettlheike tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 AT klugstefaniej tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011 |